- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.11.25 | J&J's Darzalex gains first FDA approval in smouldering multiple myeloma | ||
| 07.11.25 | Trump hits long-term pledge as US prices of weight loss drugs slashed | ||
| 07.11.25 | Abzena and Mabqi partner for drug development solution | ||
| 07.11.25 | Alvotech and Advanz announce MHRA marketing authorisations for Gobivaz | ||
| 06.11.25 | J&J's Caplyta wins MDD approval to extend revenue horizon | ||
| 06.11.25 | Former blockbuster Linzess grows label with paediatric IBS-C approval | ||
| 06.11.25 | Novo Nordisk's oral Wegovy reduces cardiovascular risk factors in obesity | ||
| 06.11.25 | Cencora to invest $1bn in US pharma distribution network | ||
| 06.11.25 | Leukogene Therapeutics gains FDA ODD status for M2T-CD33 | ||
| 05.11.25 | Novo Nordisk latest outlook trim shows "quick momentum loss" | ||
| 05.11.25 | Agentic, deeply embedded AI constitutes the "next wave" of tech | ||
| 05.11.25 | Avant and SGAustria form JV to develop diabetes therapy | ||
| 05.11.25 | Novo Nordisk and Pfizer's bidding war for Metsera escalates despite legal threats | ||
| 05.11.25 | MSD secures $700m for broad-cancer ADC asset | ||
| 05.11.25 | AmacaThera and Pacira sign agreement for AMT-143 | ||
| 05.11.25 | Boehringer and CDR-Life announce licensing deal for autoimmune disease therapy | ||
| 04.11.25 | FDA halts uniQure's plans for Huntington's disease gene therapy | ||
| 04.11.25 | Tidmarsh's FDA exit marks latest high-profile jockeying at US agencies | ||
| 04.11.25 | Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn | ||
| 04.11.25 | FDA approves UCB's Kygevvi for genetic mitochondrial disease | ||
| 04.11.25 | Eli Lilly to invest $3bn in new Dutch manufacturing facility | ||
| 04.11.25 | Alvotech faces FDA setback for its Simponi biosimilar AVT05 | ||
| 03.11.25 | Pfizer hits Novo Nordisk and Metsera with lawsuit amid bidding war | ||
| 03.11.25 | IntoCell and Xcellon Biologics to advance ADC development | ||
| 03.11.25 | 4DMT and Otsuka to advance eye disease treatment in APAC |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .